Live from the NIH registry
Studies recruiting near Fredericksburg right now
Top 25 of 36 recruiting studies, sorted by proximity — each links to its official registry page
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Intestinal Neoplasms, Gastrointestinal Neoplasms
Phase 3
Interventional 800 participants sought
Virginia Cancer Specialists, PC — Woodbridge, Virginia (27.9 mi)
· Sponsor: Pfizer
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Extensive-stage Small-cell Lung Cancer
Phase 3
Interventional 621 participants sought
Hematology Oncology Associates of Fredericksburg, Inc. — Fredericksburg, Virginia (1.5 mi)
· Sponsor: BioNTech SE
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Relapsed or Refractory Multiple Myeloma
Phase 3
Interventional 810 participants sought
Local Institution - 0297 — Fredericksburg, Virginia (1.5 mi)
· Sponsor: Celgene
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
N/A
Interventional 9,500 participants sought
Kaiser Permanente-Caton Hill Medical Center — Woodbridge, Virginia (27.9 mi)
· Sponsor: NRG Oncology
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Non-small Cell Lung Cancer
Phase 3
Interventional 876 participants sought
Hematology Oncology Associates of Fredericksburg ( Site 3275) — Fredericksburg, Virginia (1.5 mi)
· Sponsor: Merck Sharp & Dohme LLC
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Phase 3
Interventional 1,530 participants sought
Mary Washington Hospital ( Site 0129) — Fredericksburg, Virginia (1.5 mi)
· Sponsor: Merck Sharp & Dohme LLC
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer
Phase 2, Phase 3
Interventional 840 participants sought
Virginia Cancer Specialists, PC — Woodbridge, Virginia (27.9 mi)
· Sponsor: Pfizer
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
Overactive Bladder, Urinary Urgency Incontinence
N/A
Interventional 150 participants sought
Potomac Urology — Woodbridge, Virginia (27.9 mi)
· Sponsor: Axonics, Inc.
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Non-small Cell Lung Cancer
Phase 3
Interventional 675 participants sought
Hematology Oncology Associates of Fredericksburg ( Site 9550) — Fredericksburg, Virginia (1.5 mi)
· Sponsor: Merck Sharp & Dohme LLC
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Breast Cancer, Metastatic Breast Cancer
Phase 3
Interventional 404 participants sought
Hematology-Oncology Associates of Fredericksburg, Inc — Fredericksburg, Virginia (1.5 mi)
· Sponsor: BriaCell Therapeutics Corporation
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Breast Carcinoma, Colorectal Carcinoma
N/A
Observational 2,000 participants sought
Hematology Oncology Associates of Fredericksburg Inc — Fredericksburg, Virginia (1.5 mi)
· Sponsor: Wake Forest University Health Sciences
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Atrial Fibrillation (AF)
Phase 3
Interventional 2,500 participants sought
Anthos Investigational site 9817 — Fredericksburg, Virginia (1.5 mi)
· Sponsor: Anthos Therapeutics, Inc.
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Neoplasms, Head and Neck
Phase 3
Interventional 864 participants sought
GSK Investigational Site — Fredericksburg, Virginia (1.5 mi)
· Sponsor: GlaxoSmithKline
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
Renal Insufficiency, Chronic
Phase 3
Interventional 2,800 participants sought
Research Site — Woodbridge, Virginia (27.9 mi)
· Sponsor: AstraZeneca
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
Breast Cancer, Cognitive Impairments
N/A
Interventional 386 participants sought
Kaiser Permanente-Caton Hill Medical Center — Woodbridge, Virginia (27.9 mi)
· Sponsor: NRG Oncology
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Phase 3
Interventional 320 participants sought
Hematology Oncology Associates of Fredericksburg Inc — Fredericksburg, Virginia (1.5 mi)
· Sponsor: National Cancer Institute (NCI)
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
Chronic Kidney Disease and Hypertension
Phase 2
Interventional 218 participants sought
Research Site — Woodbridge, Virginia (27.9 mi)
· Sponsor: AstraZeneca
A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)
Primary Immune Thrombocytopenia
Phase 3
Interventional 126 participants sought
Hematology Oncology Associates of Fredericksburg — Fredericksburg, Virginia (1.5 mi)
· Sponsor: Amgen
Product Surveillance Registry
Cardiac Rhythm Disorders, Urological Disorders
N/A
Observational 100,000 participants sought
Research site — Fredericksburg, Virginia (1.5 mi)
· Sponsor: Medtronic
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Chronic Kidney Disease and Hypertension
Phase 3
Interventional 5,000 participants sought
Research Site — Woodbridge, Virginia (27.9 mi)
· Sponsor: AstraZeneca
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Follicular Lymphoma
Phase 3
Interventional 400 participants sought
Hematology Oncology Associates of Fredericksburg — Fredericksburg, Virginia (1.5 mi)
· Sponsor: Celgene
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Phase 3
Interventional 3,680 participants sought
Hematology Oncology Associates of Fredericksburg Inc — Fredericksburg, Virginia (1.5 mi)
· Sponsor: National Cancer Institute (NCI)
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Phase 3
Interventional 1,295 participants sought
Kaiser Permanente-Caton Hill Medical Center — Woodbridge, Virginia (27.9 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Phase 3
Interventional 1,260 participants sought
Hematology Oncology Associates of Fredericksburg Inc — Fredericksburg, Virginia (1.5 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Phase 2
Interventional 56 participants sought
Kaiser Permanente-Caton Hill Medical Center — Woodbridge, Virginia (27.9 mi)
· Sponsor: SWOG Cancer Research Network